BMS and Pfizer reach settlement with Teva

Bristol-Myers Squibb (BMS) and Pfizer have settled their dispute with Teva over an Abbreviated New Drug Application (ANDA).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BMS sues Mylan to block Reyataz generic

20 March 2015 Bristol-Myers Squibb has sued generic drug maker Mylan for allegedly infringing a patent covering its HIV drug Reyataz.

Americas

Actavis and Pfizer settle Celebrex litigation

29 April 2014 Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

Americas

BMS, Pfizer win patent dispute over blockbuster drug, Eliquis

6 September 2021 In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis.

More on this story

Americas

BMS sues Mylan to block Reyataz generic

20 March 2015 Bristol-Myers Squibb has sued generic drug maker Mylan for allegedly infringing a patent covering its HIV drug Reyataz.

Americas

Actavis and Pfizer settle Celebrex litigation

29 April 2014 Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

Americas

BMS, Pfizer win patent dispute over blockbuster drug, Eliquis

More on this story

Americas

BMS sues Mylan to block Reyataz generic

20 March 2015 Bristol-Myers Squibb has sued generic drug maker Mylan for allegedly infringing a patent covering its HIV drug Reyataz.

Americas

Actavis and Pfizer settle Celebrex litigation

29 April 2014 Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

Americas

BMS, Pfizer win patent dispute over blockbuster drug, Eliquis